Evidence map›Paper›PMID 38097263›Full record

ArticleBMJ (Clinical research ed.)2023

Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study.

Nir Balaban, Ghulam Rehman Mohyuddin, Adi Kashi, Amir Massarweh, Gal Markel, David Bomze, Daniel A Goldstein, Tomer Meirson

Abstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Nir BalabanFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ghulam Rehman MohyuddinDivision of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Adi KashiFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Amir MassarwehDavidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.
Gal MarkelFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
David BomzeFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Daniel A GoldsteinFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Tomer MeirsonFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-5011-5477

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo characterise redactions in clinical trials and estimate a time when all protocols are fully removed (RAPTURE).

designRedacted cross sectional study.

settingPublished phase 3 randomised controlled trials from 1 January 2010 to ██████████████.

participants

main outcome measures█████ ████████ ██████████████ ██████ ██████████ ████████ ████████ ██████████ ███████████ ████████████ ████████████ ████████████████████████ ██████████████████

results████████████████████ met the inclusion criteria, with 268 (56.7%) research protocols available and accessible. The rate of redactions in protocols has increased from 0 in 2010 to 60.8% in 2021 (P<0.001). The degree of data redaction has also increased, with the average cumulative redactions among industry funded trials rising from 0 in 2010 to 3.5 pages in 2021 (P<0.001). Modelling predicts that RAPTURE is expected to occur between 2073 and 2136. Redactions featured predominantly in ████████ sponsored trials and mostly occurred in the statistical design.

conclusionsThis study highlights the rise in protocol redactions and predicts that, ██████████████████████████████████████████ will be entirely redacted between 2073 and 2136. A legitimate rationale for the redactions could ███ be found. A multipronged strategy against protocol redactions is required to maintain the integrity of science. AVAILABILITY: This paper is partially redacted, but for the sake of ███████████, a version without any redactions can be found in the supplementary material.

Indexed as

COVID-19Clinical Trial Protocols as TopicCross-Sectional StudiesHumansResearch DesignSARS-CoV-2Treatment OutcomeUnited States

Identifiers

PMID38097263
PMCPMC10719744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.